title: [Concurrent chemoradiotherapy compared with concurrent chemoradiotherapy with surgery in locally advanced resectable esophageal cancer].
abstract: OBJECTIVE
  This study was designed to compare the survival rates between patients with localized esophageal cancer who were treated with concurrent chemoradiation therapy without surgery and patients who were treated with concurrent chemoradiation therapy including surgery.
  
  
  METHODS
  Eighty-eight patients from January 1997 to December 2005 with locally advanced resectable esophageal cancer were selected and retrospectively analyzed. Survival period was defined as the time to death from the date of diagnosis or mid-monitor period of December 2005. Sixty-one patients were treated with chemoradiation therapy alone while twenty-seven patients were treated with chemoradiation therapy in addition to surgery as for curative intention. As for radiation therapy, 5,000-5,500 cGY was used. 5-Fluouracil and cisplatin were used for chemotherapy. The primary end point was overall survival time. The secondary end point was overall progression free survival time.
  
  
  RESULTS
  There was no significant difference in tissue type, location and clinical staging, but the median age was significantly younger in the group treated with surgery (63.4 years) than the group treated without surgery (68.8 years). Median period analyzed was 17.3 months. Five year survival rate for the group with chemoradiation alone was 7.4% and 4% for the group with surgery. The median survival rate was 11+/-3 months for the group with chemoradiation alone and 10+/-6 months for the group with surgery, in which there was no statistical difference (p=0.697).
  
  
  CONCLUSIONS
  There was no significant increase in survival rate in patients who were treated by chemoradiation with surgery compared with chemoradiation alone. Further analysis in terms of prospective study is needed.
authors.affiliation: Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
authors.forename: Yun Ah
authors.initials: YA
authors.lastname: Choi
authors.forename: Hyung Gil
authors.initials: HG
authors.lastname: Kim
authors.forename: Seok
authors.initials: S
authors.lastname: Jung
authors.forename: Don Haeng
authors.initials: DH
authors.lastname: Lee
authors.forename: Jung Il
authors.initials: JI
authors.lastname: Lee
authors.forename: Jin Woo
authors.initials: JW
authors.lastname: Lee
authors.forename: Jung Yeup
authors.initials: JY
authors.lastname: Park
authors.forename: Yong Woon
authors.initials: YW
authors.lastname: Shin
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Kim
authors.forename: Kwang Ho
authors.initials: KH
authors.lastname: Kim
authors.forename: Young Han
authors.initials: YH
authors.lastname: Yun
authors.forename: Jun Kyu
authors.initials: JK
authors.lastname: No
authors.forename: Chul Soo
authors.initials: CS
authors.lastname: Kim
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003627:Data Interpretation, Statistical; D004938:Esophageal Neoplasms / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents